CoChat

Effectiveness of Atomoxetine and Quality of Life in Children with Attention-Deficit/Hyperactivity Disorder as Perceived by Patients, Parents, and Physicians in an Open-Label Study

Wehmeier, Peter M., Dittmann, Ralf W., Schacht, Alexander, Minarzyk, Anette, Lehmann, Martin, Sevecke, Kathrin, Lehmkuhl, Gerd · 2007 · Journal of Child and Adolescent Psychopharmacology
Cited by 30

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Health-related quality of life in children with attention-deficit/hyperactivity disorder (ADHD) may improve with atomoxetine treatment. However, the degree of improvement may be perceived differently by patients, parents, and physicians. The primary aim of this study was to investigate ADHD-related difficulties as perceived from these three perspectives and to compare the perspectives. The degree of perceived difficulties was taken to reflect the health-related quality of life of patients in the study. A second objective was to assess the effectiveness of atomoxetine in children with ADHD in an open-label setting. METHODS: Children aged 6-11 years with ADHD were treated for 24 weeks with atomoxetine at a target dose of 0.5-1.2 mg/kg per day. ADHD-related difficulties were assessed after 8 and 24 weeks of treatment using the newly devised Global Impression of Perceived Difficulties (GIPD) scale. This instrument, that has not yet been psychometrically validated, reflects patient quality of life from the three perspectives. Agreement among the perspectives was determined using Cohen's kappa. RESULTS: A total of 262 patients was treated with atomoxetine. The mean dose for the respective visit intervals ranged between 1.15 and 1.17 mg/kg per day. Quality of life as reflected by the degree of perceived difficulties improved over time. Change in GIPD scores was greatest within the first 2 weeks. The course of the mean GIPD total scores over time showed a similar pattern among the three different rater perspectives. However, patients perceived the degree of difficulties as significantly less compared to parents and physicians. Agreement of ratings was highest between physicians and parents. CONCLUSIONS: Results from the GIPD suggest that patient quality of life improves with time on atomoxetine. The effectiveness of atomoxetine in an open-label study was very similar to the effectiveness shown in placebo-controlled trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/cap.2007.0025

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 30

Metadata

Authors
Wehmeier, P. M., Dittmann, R. W., Schacht, A., Minarzyk, A., Lehmann, M., Sevecke, K., & Lehmkuhl, G.
Venue
Journal of Child and Adolescent Psychopharmacology
Published
2007-12
Volume
17
Issue
6
Pages
813-830
ISSN
  • 1044-5463 (ISSN-L)
  • 1557-8992
OpenAlex
W2011056969
Cited by
30
References
10
FWCI
3.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of Atomoxetine and Quality of Life in Children with Attention-Deficit/Hyperactivity Disorder as Perceived by Patients, Parents, and Physicians in an Open-Label Study. https://app.cochat.ai/papers/10.1089/cap.2007.0025
The paper
Wehmeier, P. M., Dittmann, R. W., Schacht, A., Minarzyk, A., Lehmann, M., Sevecke, K., & Lehmkuhl, G. (2007). Effectiveness of Atomoxetine and Quality of Life in Children with Attention-Deficit/Hyperactivity Disorder as Perceived by Patients, Parents, and Physicians in an Open-Label Study. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2007.0025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.